Clinical Trial Update: Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating inetetamab with rapamycin and chemotherapy for HER2-positive metastatic breast cancer with abnormal PAM pathway activation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Inetetamab (inetetamab)
• Rapamycin (sirolimus)

Snippet

Sponsor: Peking Union Medical College | Conditions: Breast Cancer | Phase 3 | Status: NOT_YET_RECRUITING